Overview of CDK9 as a target in cancer research
Fatima Morales1, Antonio Giordano1,2
1a Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University , Philadelphia , PA , USA.
Abstract:
CDK9 is a protein in constant development in cancer therapy. Herein we present an overview of the enzyme as a target for cancer therapy. We provide data on its characteristics and mechanism of action. In recent years, CDK9 inhibitors that have been designed with molecular modeling have demonstrated good antitumoral activity in vitro. Clinical studies of the drugs flavopiridol, dinaciclib, seliciclib, SNS-032 and RGB-286638 used as CDK9 inhibitors are also reviewed, with their additional targets and their relative IC50 values. Unfortunately, treatment with these drugs remains unsuccessful and involves many adverse effects. We could conclude that there are many small molecules that bind to CDK9, but their lack of selectivity against other CDKs do not allow them to get to the clinical use. However, drug designers currently have the tools needed to improve the selectivity of CDK9 inhibitors and to make successful treatment available to patients.
Insights
Cyclin-dependent kinase 9 (CDK9) inhibitors show promise in cancer therapy but face challenges with selectivity and side effects. Improved drug design could lead to effective CDK9-targeted cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cyclin-dependent kinase 9 (CDK9) is a key regulator of transcription and a developing target for cancer therapy.
- CDK9 plays a crucial role in cellular processes, making it an attractive target for anti-cancer drug development.
Purpose of the Study:
- To provide an overview of CDK9 as a target for cancer therapy.
- To review the characteristics, mechanism of action, and clinical studies of CDK9 inhibitors.
Main Methods:
- Literature review of CDK9 characteristics and mechanism of action.
- Analysis of in vitro antitumoral activity of CDK9 inhibitors designed with molecular modeling.
- Review of clinical studies for CDK9 inhibitors including flavopiridol, dinaciclib, seliciclib, SNS-032, and RGB-286638.
Main Results:
- CDK9 inhibitors designed via molecular modeling demonstrated in vitro antitumoral activity.
- Clinical studies of several CDK9 inhibitors revealed limited success and significant adverse effects.
- Lack of selectivity against other cyclin-dependent kinases (CDKs) is a major limitation for current CDK9 inhibitors.
Conclusions:
- Despite promising in vitro data, current CDK9 inhibitors face challenges in clinical application due to off-target effects and toxicity.
- Further advancements in drug design are necessary to enhance the selectivity of CDK9 inhibitors.
- Improved selectivity holds the potential for developing successful CDK9-targeted cancer therapies.
More Related Videos
12:26Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
Published on: May 3, 2018
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:15M-Cdk Drives Transition Into Mitosis
02:34Inhibition of Cdk Activity
02:34Inhibition of CDK Activity
02:39Positive Regulator Molecules
02:38S-Cdk Initiates DNA Replication